MRSN Stock Overview
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mersana Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.85 |
| 52 Week High | US$9.62 |
| 52 Week Low | US$0.80 |
| Beta | 1.51 |
| 1 Month Change | -33.72% |
| 3 Month Change | -11.49% |
| 1 Year Change | -23.39% |
| 3 Year Change | -82.81% |
| 5 Year Change | -40.50% |
| Change since IPO | -79.64% |
Recent News & Updates
Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%
Apr 25
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry
Feb 27Recent updates
Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%
Apr 25Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry
Feb 27Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock
Jan 11Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money
Oct 14Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Jun 09Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price
Feb 22Mersana gains as FDA grants fast track status for breast cancer drug
Sep 12Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed
Aug 15Taking The Measure Of Mersana Therapeutics
Jan 10Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress
Jun 29It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year
Jun 05Mersana Therapeutics EPS misses by $0.11, misses on revenue
May 10Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Mar 23Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?
Jan 29
Bain Capital discloses 4.8% stake in Mersana Therapeutics
Jan 13Mersana: XMT-1536's Complications, New CMO, And 2H 2021's Critical Catalyst
Jan 11Mersana slumps as XMT-1536 shows lower response rate in ovarian cancer study
Jan 05Is Mersana Therapeutics, Inc. (NASDAQ:MRSN) Trading At A 42% Discount?
Dec 08Mersana Therapeutics EPS misses by $0.02
Nov 09Shareholder Returns
| MRSN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.7% | 1.0% | 1.2% |
| 1Y | -23.4% | 0.7% | 24.9% |
Return vs Industry: MRSN underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: MRSN underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| MRSN volatility | |
|---|---|
| MRSN Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRSN's share price has been volatile over the past 3 months.
Volatility Over Time: MRSN's weekly volatility has decreased from 20% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 123 | Marty Huber | www.mersana.com |
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
Mersana Therapeutics, Inc. Fundamentals Summary
| MRSN fundamental statistics | |
|---|---|
| Market cap | US$349.35m |
| Earnings (TTM) | -US$171.67m |
| Revenue (TTM) | US$36.86m |
9.4x
P/S Ratio-2.0x
P/E RatioIs MRSN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRSN income statement (TTM) | |
|---|---|
| Revenue | US$36.86m |
| Cost of Revenue | US$148.27m |
| Gross Profit | -US$111.41m |
| Other Expenses | US$60.26m |
| Earnings | -US$171.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.42 |
| Gross Margin | -302.30% |
| Net Profit Margin | -465.80% |
| Debt/Equity Ratio | 68.4% |
How did MRSN perform over the long term?
See historical performance and comparison